2025-04-11 - Analysis Report
## Johnson & Johnson (JNJ) Stock Review

**0. Key Figures Summary:**

JNJ's cumulative return significantly lags behind the S&P 500 (VOO) over the analyzed period.  Recent price action shows a downward trend, indicated by moving averages.  Financial indicators reveal mixed signals, with low RSI suggesting potential oversold conditions but negative PPO pointing towards bearish momentum. Earnings show some volatility but generally maintain high profit margins.

**1. Performance Comparison with S&P 500:**

Johnson & Johnson (JNJ) is a multinational corporation that manufactures and sells medical devices, pharmaceuticals, and consumer packaged goods.

* **JNJ Cumulative Return:** 23.67%
* **VOO (S&P 500) Cumulative Return:** 65.78%
* **Return Difference:** -42.1%  (This indicates JNJ underperformed VOO by 42.1 percentage points.)
* **Relative Divergence Rank:** 36.5% (This means JNJ's underperformance relative to the S&P 500 is in the 36.5th percentile of historical divergence, suggesting it's not exceptionally unusual but still below average.)

**Alpha and Beta Analysis:**

The provided data shows inconsistent alpha and beta values across different time periods. While beta generally hovers around 0, indicating low sensitivity to market movements, the alpha fluctuates between negative and positive values, indicating periods of both outperformance and underperformance relative to the market. The market capitalization (Cap(B)) has generally increased over the years.  Note that a constant beta of 0 is unlikely to be true in real market data, and further detailed investigation would be needed.

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | 28.0% | 56.0% | -1.0% | 0.0 | 275.3 |
| 2016-2018  | 10.0% | 10.8% | -7.0% | 0.0 | 261.2 |
| 2017-2019  | 20.0% | 10.8% | 0.7 | 0.0 | 303.6 |
| 2018-2020  | 14.0% | 59.8% | 0.5 | 0.0 | 336.4 |
| 2019-2021  | 28.0% | 59.9% | 0.3 | 0.0 | 374.9 |
| 2020-2022  | 4.0% | 61.2% | 0.3 | 0.0 | 397.3 |
| 2021-2023  | -19.0% | 61.2% | 0.4 | 0.0 | 363.2 |
| 2022-2024  | -31.0% | 61.2% | 0.3 | 0.0 | 345.7 |
| 2023-2025  | -3.0% | 69.6% | 0.2 | 0.0 | 358.3 |


**2. Recent Price Movement:**

* **Closing Price:** $148.69
* **5-Day Moving Average:** $150.70
* **20-Day Moving Average:** $159.01
* **60-Day Moving Average:** $157.20

The stock price is currently below all three moving averages, suggesting a downtrend.  The recent price change of -$1.51 from the previous close indicates a short-term decline.


**3. Technical Indicators:**

* **Market Risk Indicator (MRI):** 0.4292 (Medium Risk)
* **RSI:** 31.16 (Approaching oversold territory, but not definitively so.)
* **PPO:** -1.02 (Negative value indicates bearish momentum.)
* **20-Day Relative Divergence Change:** -2.4% (Short-term weakening.)
* **Expected Return (2+ years):** -48.3% (This suggests a significant underperformance relative to the S&P 500 is expected over the long term based on current conditions. This needs further investigation and context.)

The recent price drop (-$1.51) does reflect a short term bearish sentiment, but isn't significant enough to classify as a "crash".


**4. Recent Earnings Analysis:**

| Date       | EPS    | Revenue       |
|------------|--------|----------------|
| 2024-10-23 | $1.12  | $22.47B        |
| 2024-07-25 | $1.95  | $22.45B        |
| 2024-05-01 | $1.35  | $21.38B        |
| 2024-02-16 | $1.68  | $21.39B        |
| 2023-10-27 | $10.32 | $21.35B        |

EPS shows significant volatility. The unusually high EPS in October 2023 needs further investigation to understand the underlying reason. Revenue remains relatively stable.

**5. Financial Information:**

**Revenue and Profitability:**

| Quarter | Revenue  | Profit Margin |
|---------|----------|---------------|
| 2024-12-31 | $22.52B | 68.35%       |
| 2024-09-30 | $22.47B | 69.01%       |
| 2024-06-30 | $22.45B | 69.40%       |
| 2024-03-31 | $21.38B | 69.55%       |
| 2023-12-31 | $21.39B | 68.23%       |

Revenue is relatively stable, and profit margins remain consistently high.

**Capital and Profitability:**

| Quarter | Equity   | ROE    |
|---------|----------|--------|
| 2024-12-31 | $71.49B | 4.80%  |
| 2024-09-30 | $70.16B | 3.84%  |
| 2024-06-30 | $71.54B | 6.55%  |
| 2024-03-31 | $70.02B | 4.65%  |
| 2023-12-31 | $68.77B | 5.89%  |

Equity fluctuates, and ROE shows some variability but remains positive.


**6. Overall Analysis:**

JNJ's recent performance lags behind the S&P 500, showing a significant negative return difference.  Technical indicators suggest a bearish short-term trend, with the price below its moving averages and negative PPO.  However, the RSI is approaching oversold levels, potentially signaling a bounce.  The consistently high profit margins and generally stable revenue are positive factors, but the volatility in EPS and the negative long-term expected return raise concerns.  Further investigation is needed into the exceptionally high EPS in Q4 2023 and the factors contributing to the projected negative long-term return relative to the S&P 500. The -48.3% expected return is a significant warning sign and should not be taken lightly, requiring further scrutiny of the underlying assumptions.  The data presents a mixed picture, requiring more in-depth analysis before making any investment decisions.
